Literature DB >> 36269426

Healthcare organizational factors associated with delayed therapeutic hypothermia in neonatal hypoxic-ischemic encephalopathy: the LyTONEPAL cohort.

Véronique Pierrat1,2, Anne Ego3,4, Jonathan Beck5,6, Thierry Debillon7, Isabelle Guellec1,8, Antoine Vilotitch3, Gauthier Loron9,10, Nathalie Bednarek9,10, Pierre-Yves Ancel1,11.   

Abstract

Initiation of therapeutic hypothermia (TH) within 6 h of life is a major concern for treating neonatal hypoxic ischemic encephalopathy (HIE). We aimed to determine clinical and healthcare organizational factors associated with delayed TH in a French population-based cohort of neonates with moderate/severe HIE. Time to reach a rectal temperature of 34 °C defines optimal and delayed (within and over 6 h, respectively) TH. Clinical and healthcare organizational factors associated with delayed TH were analysed among neonates born in cooling centres (CCs) and non-cooling centres (non-CCs). Among 629 neonates eligible for TH, 574 received treatment (91.3%). TH was delayed in 29.8% neonates and in 20.3% and 36.2% of those born in CCs and non-CCs, respectively. Neonates with moderate HIE were more exposed to delayed TH in both CCs and non-CCs. After adjustment for HIE severity, maternal and neonatal characteristics and circumstances of birth were not associated with increased risk of delayed TH. However, this risk was 2 to 5 times higher in maternities with < 1999 annual births, when the delay between birth and call for transfer (adjusted odds ratio [aOR] 2.47, 95% confidence interval [CI] [1.03 to 5.96]) or between call for transfer and admission (aOR 6.06, 95%CI [2.60 to 14.12]) was > 3 h and when an undesirable event occurred during transfer (aOR 2.66, 95%CI [1.11 to 6.37]. 
Conclusion: Increasing early identification of neonates who could benefit from TH and access to TH in non-CCs before transfer are modifiable factors that could improve care of neonates with HIE.  Trial registration: The trial was registered at ClinicalTrials.gov (NCT02676063). What is Known: • International recommendations are to initiate therapeutic hypothermia before 6 h of life in neonates with moderate or severe hypoxic ischemic encephalopathy. What is New: •In this French population-based cohort of infants with hypoxic ischemic encephalopathy, nearly one-third of neonates eligible for treatment did not have access to hypothermia in the therapeutic window of 6 h of life. . • Among infants born in non-cooling centres, healthcare organizational factors involved in delayed care were the small size of maternities (1999 annual births), a time interval of more than 3 h between birth and call for transfer and between call for transfer and admission in neonatology, and the occurrence of an undesirable event during transfer.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cohort study; Hypoxic ischemic encephalopathy; Neonate; Therapeutic hypothermia

Year:  2022        PMID: 36269426     DOI: 10.1007/s00431-022-04666-7

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.860


  21 in total

1.  Improving the quality of health care in the United Kingdom and the United States: a framework for change.

Authors:  E B Ferlie; S M Shortell
Journal:  Milbank Q       Date:  2001       Impact factor: 4.911

2.  The relation between the availability of neonatal intensive care and neonatal mortality.

Authors:  David C Goodman; Elliott S Fisher; George A Little; Thérèse A Stukel; Chiang-hua Chang; Kenneth S Schoendorf
Journal:  N Engl J Med       Date:  2002-05-16       Impact factor: 91.245

3.  Providing active antenatal care depends on the place of birth for extremely preterm births: the EPIPAGE 2 cohort study.

Authors:  Caroline Diguisto; François Goffinet; Elsa Lorthe; Gilles Kayem; Jean-Christophe Roze; Pascal Boileau; Babak Khoshnood; Valérie Benhammou; Bruno Langer; Loic Sentilhes; Damien Subtil; Elie Azria; Monique Kaminski; Pierre-Yves Ancel; Laurence Foix-L'Hélias
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2017-06-30       Impact factor: 5.747

Review 4.  Therapeutic Hypothermia in Neonatal Hypoxic-Ischemic Encephalopathy.

Authors:  Guido Wassink; Joanne O Davidson; Simerdeep K Dhillon; Kelly Zhou; Laura Bennet; Marianne Thoresen; Alistair J Gunn
Journal:  Curr Neurol Neurosci Rep       Date:  2019-01-14       Impact factor: 5.081

Review 5.  Hypothermia for newborns with hypoxic-ischemic encephalopathy.

Authors:  Brigitte Lemyre; Vann Chau
Journal:  Paediatr Child Health       Date:  2018-06-12       Impact factor: 2.253

Review 6.  Mechanisms of hypothermic neuroprotection.

Authors:  Paul P Drury; Eleanor R Gunn; Laura Bennet; Alistair J Gunn
Journal:  Clin Perinatol       Date:  2013-12-12       Impact factor: 3.430

7.  Introduction of hypothermia for neonates with perinatal asphyxia in the Netherlands and Flanders.

Authors:  Floris Groenendaal; Alexandra Casaer; Koen P Dijkman; Antonio W D Gavilanes; Timo R de Haan; Henk J ter Horst; Sabine Laroche; Gunnar Naulaers; Monique Rijken; Henrica L M van Straaten; Katerina Steiner; Renate M C Swarte; Alexandra Zecic; Inge A Zonnenberg
Journal:  Neonatology       Date:  2013-04-23       Impact factor: 4.035

8.  Delivery room management of extremely preterm infants: the EPIPAGE-2 study.

Authors:  J Perlbarg; P Y Ancel; B Khoshnood; M Durox; P Boileau; M Garel; M Kaminski; F Goffinet; L Foix-L'Hélias
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2016-02-02       Impact factor: 5.747

9.  Adherence to hypothermia guidelines: a French multicenter study of fullterm neonates.

Authors:  Marie Chevallier; Anne Ego; Christine Cans; Thierry Debillon
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

10.  LyTONEPAL: long term outcome of neonatal hypoxic encephalopathy in the era of neuroprotective treatment with hypothermia: a French population-based cohort.

Authors:  Thierry Debillon; Nathalie Bednarek; Anne Ego
Journal:  BMC Pediatr       Date:  2018-08-01       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.